Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending oral dose study of ASP2905 in healthy young men, with fed versus fasted pharmacokinetic crossover
NL-OMON32022Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ASP2905 in Alzheimer's disease (AD) and schizophrenia (3 arms), sponsored by Astellas Pharma. Primary endpoints: Safety and tolerability, Pharmacokinetics and 1 more. Started May 2008; status: active, not recruiting.
02
Drugs
ASP2905
03
Conditions
Alzheimer's disease (AD)schizophrenia
Beyond the preview
Go deeper on NL-OMON32022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32022.